Advert Novartis – Case AUTH/3633/4/22
-
Date posted18 October 2023
-
SanctionAdvertisement,
-
Case number/s
For providing some, but not all, the relevant information in relation to renal and hepatic impairment in the body of a webpage which was intended to advise health professionals on considerations when using Entresto (sacubitril/valsartan) which was misleading, Novartis was ruled in breach of the following clauses of the 2021 Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Providing misleading information